Beyond Xeljanz: An Inflammation & Immunology Portfolio Blooms At Pfizer
Executive Summary
Xeljanz’s launch in rheumatoid arthritis has gotten off to a slower than expected start, highlighting the challenges for new drugs in competitive inflammatory diseases. But Pfizer is digging in its heels and hoping that pipeline drugs, including next-generation JAKs, will stand out by addressing unmet medical need in indications like lupus, type1 diabetes and inflammatory bowel disease.
You may also be interested in...
Pfizer’s Tofacitinib Clears FDA Without Limited Indication
With FDA’s early approval of tofacitinib for rheumatoid arthritis – the first JAK inhibitor and, unlike the popular TNF inhibitors, an oral agent – the agency appears to have sided with Pfizer on many issues left up in the air after an advisory committee review.
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.
Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More
“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.